Can a 76-year-old patient with urge incontinence whose oxybutynin therapy is no longer effective be switched to mirabegron (Myrbetriq)?

Switching from Oxybutynin to Mirabegron in a 76-Year-Old

Yes, you can and should switch this 76-year-old patient from oxybutynin to mirabegron 25 mg once daily, with potential escalation to 50 mg after 4-8 weeks if needed. This is explicitly supported by current guidelines and FDA labeling for overactive bladder management when first-line anticholinergic therapy fails 1, 2.

Guideline-Based Rationale

The 2024 AUA/SUFU guidelines establish a clear treatment pathway for OAB when initial pharmacotherapy is ineffective. When an anticholinergic like oxybutynin fails, clinicians should consider either:

• Dose modification or switching to an alternate medication (different anticholinergic or β3-adrenoceptor agonist like mirabegron)
• Combination therapy with both drug classes 1, 3

Since your patient has already failed oxybutynin monotherapy, switching to mirabegron represents the appropriate next step before considering more invasive options like botulinum toxin or neuromodulation.

FDA-Approved Dosing

Mirabegron (Myrbetriq) is FDA-approved for adult OAB with the following regimen 2:

• Start: 25 mg orally once daily
• Maximum: 50 mg orally once daily after 4-8 weeks if needed

Evidence in Elderly Patients

The safety and efficacy data specifically support mirabegron use in patients aged ≥75 years:

• A large Japanese post-marketing study (n=9,795) demonstrated that mirabegron was well-tolerated in patients ≥75 years, with adverse drug reaction rates of 7.00% versus 5.19% in younger patients—a clinically acceptable difference 4

• Treatment effectiveness was 79.3% in patients ≥75 years, with 61% achieving minimal clinically important change in symptom scores 4

• A dedicated study in frail patients ≥80 years (median age 84) showed significant improvements in urgency, urge incontinence, and quality of life with excellent tolerability 5

• Treatment persistence was actually higher in patients ≥65 years (67.3%) compared to younger patients (59.8%) at 1 year 6

Safety Considerations for This Patient

Before switching, you should:

1. Measure post-void residual (PVR) - While not mandatory for oral medications, this establishes a baseline, especially if future botulinum toxin therapy is considered 1

2. Review cardiovascular status - Mirabegron can cause modest blood pressure increases, though studies in elderly patients showed no significant changes 5, 7

3. Check for drug interactions - Mirabegron is a moderate CYP2D6 inhibitor

4. Assess renal function - Dose adjustment may be needed in severe renal impairment

Advantages Over Continuing Anticholinergics

Mirabegron offers distinct benefits in elderly patients:

• Lower anticholinergic burden - Critical in a 76-year-old to reduce cognitive impairment risk
• Different mechanism of action (β3-adrenoceptor agonist vs. muscarinic antagonist)
• Comparable efficacy with better tolerability profile - Lower rates of dry mouth, constipation, and cognitive effects 8
• No significant increase in urinary retention compared to antimuscarinics 9

Alternative: Combination Therapy

If you prefer not to discontinue oxybutynin entirely, the 2019 AUA/SUFU amendment supports combination therapy with an antimuscarinic plus mirabegron for patients refractory to monotherapy 3. The SYNERGY and BESIDE trials demonstrated additive efficacy without substantially increased adverse events when combining solifenacin 5 mg with mirabegron 25-50 mg 3. However, switching to mirabegron monotherapy is the more straightforward initial approach given oxybutynin's failure and the patient's age.

Common Pitfalls to Avoid

• Don't start at 50 mg - Begin with 25 mg to assess tolerability in this elderly patient
• Don't expect immediate results - Allow 4-8 weeks before dose escalation
• Don't forget to discontinue oxybutynin when switching to monotherapy (unless intentionally doing combination therapy)
• Don't skip the efficacy assessment - Reassess symptoms at 4-8 weeks using validated tools like OABSS or bladder diary

Monitoring Plan

After initiating mirabegron:

• Reassess symptoms at 4-8 weeks
• Monitor blood pressure, especially in first month
• Consider dose escalation to 50 mg if 25 mg provides insufficient benefit
• If mirabegron monotherapy fails, consider adding back an antimuscarinic for combination therapy before proceeding to third-line invasive options 1, 3